US equities
|
SPCX
$167.19
▲+5.18%
NVDA
$236.40
▲+1.05%
MU
$1,064.25
▼-0.99%
TSLA
$378.27
▲+2.07%
MSFT
$525.09
▲+1.46%
SNDK
$1,708.50
▼-0.67%
INTC
$117.38
▼-1.63%
META
$743.44
▲+2.11%
SPCX
$167.19
▲+5.18%
NVDA
$236.40
▲+1.05%
MU
$1,064.25
▼-0.99%
TSLA
$378.27
▲+2.07%
MSFT
$525.09
▲+1.46%
SNDK
$1,708.50
▼-0.67%
INTC
$117.38
▼-1.63%
META
$743.44
▲+2.11%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
119.75
+3.52 (+3.02%)
Delayed Quote
Updated: 12:23 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
↗
June 29, 2022
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Via
Benzinga
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
↗
June 28, 2022
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.
Via
Investor's Business Daily
Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling
↗
June 28, 2022
Corcept makes a Cushing's drug that, by another name, causes medical abortion.
Via
Investor's Business Daily
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
↗
June 23, 2022
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.
Via
Investor's Business Daily
Top Mid-Cap Stocks: Trading Opportunities For Next Week - Sunday, June 19
↗
June 19, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some mid-cap stock opportunities by analyzing...
Via
Talk Markets
Corcept Update
May 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Alert
February 01, 2022
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their Options
Via
NewMediaWire
Corcept Investor Alert
January 31, 2022
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their Options
Via
NewMediaWire
NASDAQ:CORT Investor Alert: Investigation over Potential Wrongdoing at Corcept Therapeutics Incorporated
↗
May 09, 2022
San Diego, CA -- (SBWIRE) -- 05/09/2022 -- Certain directors of Corcept Therapeutics Incorporated are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Preview: Corcept Therapeutics's Earnings
↗
May 04, 2022
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Corcept Shareholder Notice
April 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shareholder Alert: Update on Lawsuit Against Corcept Therapeutics
↗
March 22, 2022
San Diego, CA -- (SBWIRE) -- 03/22/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Corcept Therapeutics Incorporated (NASDAQ:CORT)...
Via
SBWire
Corcept Therapeutics's Return On Capital Employed Overview
↗
February 16, 2022
According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million...
Via
Benzinga
Recap: Corcept Therapeutics Q4 Earnings
↗
February 15, 2022
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
↗
February 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...
Via
Benzinga
Corcept Update
February 13, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Notice
February 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Alert
February 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Investor Alert
February 07, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Earnings Scheduled For February 15, 2022
↗
February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.
Via
Benzinga
Corcept Update
February 06, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Notice
February 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
↗
February 02, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...
Via
Benzinga
Corcept Shareholder Notice
January 30, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Alert
January 28, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Investor Alert
January 25, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)
January 25, 2022
From
Robbins LLP
Via
Business Wire
Corcept Investor Alert
January 24, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Notice
January 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Shareholder Alert
January 17, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
